137571-76-7

Upstream product

• 628-71-7 1-Heptyne 
• 137571-74-5 7-(benzyloxy)-5-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 137571-73-4 5,7-dihydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 83-30-7 acide 2,4,6-trihydroxybenzoique 
• 137571-75-6 7-(benzyloxy)-2,2-dimethyl-5-<(trifluoromethyl)sulfonyl>-4H-1,3-benzodioxin-4-one 

Downstream Products

• 1408253-08-6 2,4-bis(benzyloxy)-6-heptylbenzoic acid 
• 1408253-05-3 benzyl 2,4-bis(benzyloxy)-6-heptylbenzoate 
• 1408253-09-7 benzyl 4-((2,4-bis(benzyloxy)-6-heptylbenzoyl)oxy)-2-heptyl-6-hydroxybenzoate 
• 137571-94-9 ent-KS-501 
• 120634-86-8 KS-501 
• 137571-93-8 3'-(benzyloxy)-6'-<<4''-<(benzyloxy)carbonyl>-5''-(1-heptyl)-3''-hydroxyphenoxy>carbonyl>-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-L-galactofuranoside 
• 137571-85-8 3'-(benzyloxy)-6'-<<4''-<(benzyloxy)carbonyl>-5''-(1-heptyl)-3''-hydroxyphenoxy>carbonyl>-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-D-galactofuranoside 
• 137571-92-7 3'-(benzyloxy)-6'-<<5''-(1-heptyl)-3''-hydroxyphenoxy>carbonyl>-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-L-galactofuranoside 
• 137571-84-7 3'-(benzyloxy)-6'-<<5''-(1-heptyl)-3''-hydroxyphenoxy>carbonyl>-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-D-galactofuranoside 
• 137571-82-5 3'-(benzyloxy)-6'-<<β-(trimethylsilyl)ethoxy>carbonyl>-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-5,6-cyclopentylidene-D-galactofuranoside 
• 137571-90-5 3'-(benzyloxy)-6'-<<β-(trimethylsilyl)ethoxy>carbonyl>-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-5,6-cyclopentylidene-L-galactofuranoside 
• 137571-83-6 3'-(benzyloxy)-6'-carboxy-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-5,6-cyclopentylidene-D-galactofuranoside 
• 137571-91-6 3'-(benzyloxy)-6'-carboxy-5'-(1-heptyn-1-yl)phenyl 2,3-di-O-benzyl-5,6-cyclopentylidene-L-galactofuranoside 
• 137571-81-4 3'-(benzyloxy)-6'-<<β-(trimethylsilyl)ethoxy>carbonyl>-5'-(1-heptyn-1-yl)phenyl 3-O-benzyl-5,6-cyclopentylidene-D-galactofuranoside 

Relevant academic research and scientific papers

First total synthesis of prasinic acid and its anticancer activity

The first total synthesis of prasinic acid is being reported along with its biological evaluation. The ten step synthesis involved readily available and cheap starting materials and can easily be transposed to large scale manufacturing. The crucial steps of the synthesis included the formation of two different aromatic units (7 and 9) and their coupling reaction. The synthetic prasinic acid exhibited moderate antitumor activity (IC50 4.3-9.1 μM) in different lines of cancer cells.

Synthesis of inhibitors of calmodulin-mediated enzymes including KS-501, KS-502 and their enantiomers

The total synthesis of a group of compounds with inhibitory effects on calmodulin-mediated enzyme activities has been accomplished. Among these synthesized compounds are KS-501 and KS-502. Other compounds that have been synthesized by the described scheme are ent-KS-501 and ent-KS-502 which are enantiomers of KS-501 and KS-502 and which also have inhibitory effects on calmodulin-mediated enzyme activities.